---
document_datetime: 2024-12-03 13:52:31
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/scientific-conclusion/kimmtrak-h-c-psusa-00010991-202401-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf
document_name: kimmtrak-h-c-psusa-00010991-202401-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf
version: success
processing_time: 0.7884038
conversion_datetime: 2025-12-23 04:44:18.338292
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

19 September 2024 EMA/430997/2024 Committee for Medicinal Products for Human Use (CHMP)

## Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Active substance(s): tebentafusp

Procedure No. EMEA/H/C/PSUSA/00010991/202401

Period covered by the PSUR: 24/07/2023 To: 24/01/2024

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for tebentafusp, the scientific conclusions of PRAC are as follows:

In view of available data on serious complications of Cytokine Release Syndrome from spontaneous reports and literature, the PRAC concluded that the product information of products containing tebentafusp should be amended accordingly.

Having reviewed the PRAC recommendation, the CHMP agrees with the PRAC overall conclusions and grounds for recommendation.

## Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for tebentafusp the CHMP is of the opinion that the benefitrisk balance of the medicinal product(s) containing tebentafusp is unchanged subject to the proposed changes to the product information

The CHMP recommends that the terms of the marketing authorisation(s) should be varied.